Trials / Completed
CompletedNCT00546000
Cutivate Lotion HPA Axis Pediatric Study
A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Fougera Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 3 Months – 12 Months
- Healthy volunteers
- Not accepted
Summary
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluticasone propionate 0.05% lotion | Daily applications |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-10-18
- Last updated
- 2014-07-24
- Results posted
- 2014-07-24
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00546000. Inclusion in this directory is not an endorsement.